ProfileGDS5678 / 1426970_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 85% 85% 92% 86% 87% 87% 86% 87% 85% 87% 84% 83% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4624286
GSM967853U87-EV human glioblastoma xenograft - Control 26.4524485
GSM967854U87-EV human glioblastoma xenograft - Control 36.4567985
GSM967855U87-EV human glioblastoma xenograft - Control 47.717792
GSM967856U87-EV human glioblastoma xenograft - Control 56.6225586
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4680987
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4451287
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4382186
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6784687
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4530285
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7200287
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3302884
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.1343783
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5672486